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Abstract
Background
In this study we used cellular magnetic resonance imaging (MRI) to detect mesenchymal
stem cells (MSC) labeled with a Fluorine-19 (19F) agent. 19F-MRI offers unambiguous de-
tection and in vivo quantification of labeled cells.
Methods
We investigated two common stem cell transplant mouse models: an immune competent,
syngeneic transplant model and an immune compromised, xenograft transplant model. 19F
labelled stem cells were implanted intramuscularly into the hindlimb of healthy mice. The
transplant was then monitored for up to 17 days using 19F-MRI, after which the tissue was
excised for fluorescence microscopy and immunohistochemisty.
Results
Immediately following transplantation, 19F-MRI quantification correlated very well with the
expected cell number in both models. The 19F signal decreased over time in both models,
with a more rapid decrease in the syngeneic model. By endpoint, only 2/7 syngeneic mice
had any detectable 19F signal. In the xenograft model, all mice had detectable signal at end-
point. Fluorescence microscopy and immunohistochemistry were used to show that the 19F
signal was related to the presence of bystander labeled macrophages, and not original
MSC.
Conclusions
Our results show that 19F-MRI is an excellent tool for verifying the delivery of therapeutic
cells early after transplantation. However, in certain circumstances the transfer of cellular
label to other bystander cells may confuse interpretation of the long-term fate of the
transplanted cells.
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Introduction
Stem cell therapy has the potential to play an important role in regenerative medicine. Mesen-
chymal stromal/stem cells (MSC) have been extensively investigated for clinical application
over the past decade.[1,2] MSC are capable of differentiating into a variety of important tissues,
such as: bone, cartilage and adipose.[3] They also display immunomodulatory properties.[4–6]
Their presence in adult tissue, and ease of expansion in vitro has made MSC good candidate
cells for clinical translation.[7,8]
In order to advance stem cell therapy, tools must be developed to monitor the survival of
implanted stem cells non-invasively after administration to the patient. Magnetic resonance
imaging (MRI) cell tracking is an effective method to visualize and monitor cells non-invasively
after implantation due to the high spatial resolution and lack of ionizing radiation.
The majority of MRI cell tracking studies have used iron oxide nanoparticles to label the
cells of interest.[9–15] When imaged with MRI, the iron nanoparticles produce a dark signal
void in T2/T2 weighted proton images. This technique is highly sensitive, permitting the im-
aging of single cells.[16,17] Limitations with tracking iron-labeled cells arise from low specifici-
ty, due to other regions in the image with low signal, and from complicated in vivo
quantification of the signal loss. Our group and others have shown that degree of signal loss
produced by iron labeled cells is only linear at low iron concentrations.[16,18] Furthermore the
high sensitivity to iron can produce ambiguity due to the strong false-positive signal produced
when even a small number of bystander cells become labeled inadvertantly.[19,20]
As an alternative to iron cell tracking, fluorine-19 (19F) MRI with perfluorocarbon (PFC)
nanoemulsions has been used for cell tracking.[21] 19F MRI is able to image implanted cells
with high specificity due to the lack of detectable fluorine in biological tissue.[22,23] Quantifi-
cation of implanted cells is possible since the 19F MRI signal intensity is linearly related to the
number of 19F-labeled cells. Unlike PET/SPECT probes, 19F does not undergo radioactive
decay allowing for longitudinal studies without radiation-induced toxicity to the implanted
cells or surrounding tissue. Furthermore, the first clinical application of 19F-MRI cell tracking
for DC immunotherapy was recently reported, showing the technique is both feasible and safe
for human application.[24]
In this paper, we investigated the feasibility of quantifying MSC survival in two different im-
mune system environments. This was performed by comparing the change in 19F-MRI signal
strength over time using two popular transplantation models. A syngeneic transplant model,
with mouse MSC (mMSC) implanted in an immune-competent mouse host, was compared to
a xenograft model produced from human MSC (hMSC) implanted in an immune-
compromised mouse. Our goals were: i) to quantify the apparent cell number non-invasively
for 2.5 weeks and ii) to validate in vivo 19F-MRI quantification results with fluorescence mi-
croscopy and immunohistochemistry.
Methods
MSC culture and labeling
hMSC came from bone marrow donated by healthy young adult volunteers after written in-
formed consent according to a protocol approved by University Health Network Research Eth-
ics Board (Toronto, Canada)[25]. hMSC were cultured as described by Ribot et al.[19] mMSC
derived from the bone marrow of C57Bl/6 mice and expressing green fluorescence protein
(GFP+) were purchased from Cyagen Bioscience Inc. (Catalog # MUBMX-01101). The cells
were cultured in OriCell Mouse MSC Growth Medium until 90% confluent. The mMSC were
passaged once before labeling and implantation.
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All MSC were labeled with the red fluorescent perfluoropolyether agent, Cell Sense (CS-
ATM-DM Red; CelSense Inc. Pittsburg, USA)[26]. Labeling took place over 24 hours at a con-
centration of 2.5mg/mL. After incubation, the cells were washed 3 times with Hank’s balanced
salt solution (HBSS), harvested with Trypsin, spun down and counted. At this stage the cells
were tested for viability using trypan blue exclusion. Intracellular 19F content of cells was deter-
mined using NMR spectroscopy, as we have described previously.[19]
MSC implantation
1.5x106 Cell Sense-labeled hMSC in 100μL of HBSS were implanted intramuscularly into the
right hindlimb muscle of immune-compromised, nude mice (nu/nu, Charles River Canada) to
produce a xenograft model (n = 7). In a similar manner, 2.0x106 labeled mMSC in 100μL of
HBSS were implanted into immune competent, C57Bl/6 mice (Jackson Laboratories) produc-
ing a syngeneic model (n = 8). In both cases, the injections were performed under 2% isoflur-
ane anesthesia. All experiments involving human and mouse stem cells, as well as animal use,
were approved by the Western University Animal Use Committee (AUP 2009–042).
MRI
All images were collected using a 9.4T Varian small-animal MRI scanner. A 3D balanced
steady state free precession (bSSFP) sequence was used for both proton and fluorine imaging.
Cell pellets containing 2x105, 4x105, 6x105, 8x105, 1x106 and 2x106 19F-labeled MSC were im-
aged alongside a reference tube of known fluorine concentration (7.3x1016 19F/μL). MRI was
performed using a dual-tuned birdcage volume coil (diameter 2.2cm, length 5.1cm), tuned to
400.2 MHz and 376.8 MHz for proton and fluorine imaging respectively. For proton imaging
of cell pellets the scan parameters were: repetition time (TR) = 3.8ms, echo time (TE) = 1.9ms,
receiver bandwidth (rBW) = 125kHz, flip angle (FA) = 30°, averages = 2, resolution =
200x200x200μm3. For fluorine imaging the parameters were: TR = 3.5ms, TE = 1.8ms, rBW =
25kHz, FA = 70°, averages = 250, resolution = 1x1x2mm3. Total protocol time for both proton
and fluorine imaging was under 90 minutes. The pellets were imaged on three separate occa-
sions to test quantification variability.
Mice containing 19F-labeled MSC implantations were imaged at four time points, starting
on day 0, after implantation. The scan parameters were the same for the in vivomouse MRI as
described previously. During scanning the mice were anesthetized with 2% isoflurane, with
breathing rate and temperature monitored. Due to the high sensitivity of bSSFP to off-
resonance frequencies[27], a narrow 1.5kHz sinc pulse was used to excite only the 19F agent.
Image analysis and quantification
Prior to image analysis, a signal correction was applied to the 19F datasets by subtracting a con-
stant value (x) from all voxels within the dataset using the image program, ImageJ.[28,29] The
value of x was equal to the signal of the single voxel containing the lowest signal throughout
the entire dataset. This linear translation acted to left-shift the data distribution to begin at
zero. Quantification was performed using Voxel Tracker software, as described by Srinivas
et al.[30] Briefly, in the 19F MR images, the signal contained within a hand drawn ROI is
summed and compared to the average signal produced by the reference tube of known concen-
tration (2.6x1016 19F spins/μL). This value (X) provides the total number of 19F spins located at
the ROI. NMR spectroscopy was then performed using a known number of the same trans-
planted cells, along with a second 19F source containing a known number of 19F spins. By com-
paring the relative NMR signals, the number of 19F spins per cell (Y) is obtained. Division of X
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by Y yields the number of cells located at the ROI. Significance between time-points was as-
sessed using a repeated measures, one-way ANOVA.
Immunohistochemistry
Mice were sacrificed and perfused with 4% paraformaldehyde following the final imaging time-
point. In addition, one mouse from each model was sacrificed and perfused on Day 0 for com-
parison. The hindlimb muscle was extracted and cryoprotected with increasing concentrations
of sucrose (10%, 20%, 30%) before freezing in OCT medium. Tissue was sectioned with a cryo-
stat. Fluorescence microscopy was performed to image the red fluorescent 19F-label as well as
the GFP+ mMSC with a Zeiss AXIO Imager microscope (Carl Zeiss Canada Ltd). Immunohis-
tochemistry staining was then performed on these sections. Macrophage presence was assessed
using Biotin anti-mouse macrophage (F4/80) monoclonal antibody (Cedarlane Laboratories
Ltd) with 3,3’-Diaminobenzidine (DAB) counterstain.
Results
Labeling of MSC with Cell Sense
Fig. 1 shows that labeling with the 19F agent did not negatively affect the mMSC cellular viabili-
ty. The viability of the hMSC was slightly decreased following labeling. Previous work by our
group demonstrated that the perfluorocarbon, Cell Sense, did not negatively impact differentia-
tion of labeled hMSC into osteogenic or adipogenic lineages.[19] NMR revealed the cellular
loading of 19F varied between experiments and cell types within the range of 8.2x1010 to
2.4x1011 atoms.
Quantification of 19F in cell samples
Quantification of the 19F signal was tested in vitro using Cell Sense labeled mMSC pellets. Im-
aging was performed at 9.4T on six cell pellets ranging from 200k to 2 million cells. Fig. 2 repre-
sents the average quantification and standard deviation from imaging the cell pellets on three
different occasions. We observed a strong linear relationship between the MR quantification
and the real cell number, with an R2 = 0.98.
In vivo detection of 19F MRI signal
19F-MRI signal was initially detectable in all mice following intramuscular injection of 2.0x106
mMSC or 1.5x106 hMSC. On day 0 quantification of the in vivo signal agreed very well with
the number of implanted cells (Fig. 3). Over time the signal decreased in both models. In the
immune competent model (Fig. 3A), a significant effect was observed in the decrease in 19F
MRI signal over time [F(1.703,6.812) = 39.85, p<0.001]. Post hoc Tukey tests showed there
was a significant difference in 19F signal between day 3 and day 9 (p<0.01), and day 9 and 16
(p<0.05). At 16 days post implantation only two mice had any detectable signal remaining. Sig-
nal in the immune-compromised mice (Fig. 3B) decreased more slowly [F(1.378,5.511) =
30.97, p<0.01], with significance from day 0 only detectable on day 17 (p<0.01). Furthermore,
at this endpoint all immune-compromised mice still had detectable signal.
Representative MR image data, fluorescence microscopy, and H&E obtained on day 0 is
shown in Fig. 4. Overlays of the 19F MRI onto the proton image at day 0 are show in 4A and E
for the immune competent and immune compromised mice respectively. Fig. 4B and F show
that the red fluorescence signal from the 19F labeling agent can be detected on day 0 in both
models. The green fluorescence associated with the GFP+ mMSC was also clearly visible at the
site of their implantation on day 0 (Fig. 4C). Overlaying the two fluorescent images revealed
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strong co-localization, with a Pearson’s correlation coefficient of 0.80, between the red fluores-
cent 19F agent and the GFP+ mMSC in Fig. 4D. The corresponding H&E stained tissue sections
reveal the location of the implant within the muscle (Fig. 4G,H).
Fig. 5 shows representative MR image data, H&E, F4/80 immunohistochemistry and fluo-
rescence microscopy obtained at the experimental endpoint. By day 16 post implantation no
19F signal from the mMSC was detectable in 5/7 of the immune competent mice. One of these
mice is shown in Fig. 5A where the only 19F signal comes from the reference tube. In contrast,
19F signal was still detectable in all of the immune compromised mice at day 17, an example is
shown in Fig. 5E.
Fluorescence microscopy revealed only a small area of red fluorescence from the 19F agent
in the immune competent model (Fig. 5B) compared to the immune compromised (Fig. 5F).
In addition, no GFP+ mMSC were detectable in ex vivo samples at endpoint. H&E staining of
the same tissue sections clearly showed cells at the site of the implant, which strongly corre-
sponded with the 19F agent’s red fluorescence (Fig. 5C,G). Neighboring tissue sections corre-
sponding to high red fluorescence were stained for the presence of macrophages using F4/80.
Fig. 5D shows that relatively few macrophages were detected in the immune competent model
Fig 1. Cellular viability and loading with the 19F-agent. (A) Cellular viability was investigated before and
after labeling with the 19F-agent, Cell Sense. Although a statistically significant difference was observed in
hMSC after labeling, the viability remained high (>80%) in all experiments. There was no significant
difference in mMSC viability. (B) Cellular loading was determined by performing NMR on a known number of
cells alongside a reference peak with a known number of 19F atoms. We observed variation in cellular loading
of both hMSC and mMSC between experiments. However, this variation does not affect in vivo 19F
quantification since each transplant was only compared to its specific cellular loading.
doi:10.1371/journal.pone.0118544.g001
Fig 2. In vitro validation of 19F-MRI quantification accuracy.Quantification was validated in a phantom
study using cell pellets ranging from 2x105 to 2x106 MSC. Pellets were imaged three times, with the error
bars representing the standard deviation between scans. The 19F-MRI quantification is in very strong
agreement with the true number of cells, and has a Pearson correlation coefficient of 0.99. The red line
represents the ideal result of a 1:1 correlation.
doi:10.1371/journal.pone.0118544.g002
MSC Fate Assessed with Fluorine MRI
PLOS ONE | DOI:10.1371/journal.pone.0118544 March 13, 2015 5 / 11
at endpoint. In contrast, the F4/80 stain revealed large numbers of macrophages (Fig. 5H) in
the same region as the red fluorescence from the 19F agent in the immune compromised
model. The number of macrophages shows very strong correspondence to the amount of re-
maining red fluorescence in both cases.
An important additional finding worth noting was that 19F signal due to the use of inhala-
tional isoflurane anesthesia could be eliminated by using a narrow 1.5 kHz sinc excitation
pulse. S1 Fig. shows that a broader 3kHz RF pulse led to substantial background 19F signal in
the mouse body. Isoflurane becomes concentrated within fat pads during imaging[31] and
these high levels of 19F signal can lead to false-positive detection and incorrect quantification.
Fig 3. Comparison of 19F-labeled cell detection in two transplantation models over time. (A) Following implantation of 2x106 mMSC, 19F-MRI was used
to quantify the number of cells remaining over 16 days. By day 16, only 2/7 mice had any detectable signal remaining. A significant difference from day 0 is
denoted by +, from day 3 by◆, and from day 9 by■. (B) The number of detectable cells over a similar time period following a transplant of 1.5x106 hMSC. 19F signal
was found to decrease at a slower rate, with observable signal in all mice at endpoint. Statistical significance is denoted in the same way as A.
doi:10.1371/journal.pone.0118544.g003
Fig 4. Representative Day 0 MRI, fluorescence microscopy, and histology acquired as 10xmagnification from both implant models. (A, E)
Representative MRI frommice receiving either 2x106 mMSC or 1.5x106 hMSC respectively. The day 0 in vivo 19F-MRI quantification correlates very well with
the number of implanted cells. The reference tube is marked by “R”. (B) The red fluorescent fluorine agent is clearly visible in the tissue of the immune
competent model, (F) as well as in the immune-compromised model. (C) Furthermore, the GFP+mMSC are observable within the tissue section. (D)
Overlaying the two fluorescent images, reveals the 19F agent colocalized with the GFP+mMSC, as expected. (G, H) H&E stained tissue sections
corresponding to the fluorescence microscopy clearly show the implant site of the mMSC and hMSC respectively. Scale bars in all images represent 250μm.
doi:10.1371/journal.pone.0118544.g004
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Isoflurane anesthesia is preferred for the ease of use and the relatively long imaging times re-
quired for 19F MRI. Another option is ketamine/xylazine but this requires the use of an intrave-
nous or intraperitoneal catheter and infusion pump in order to maintain effectiveness over the
time period required which can be challenging in mice.[32–34] Pentobarbital is also capable of
providing anesthetic for over 2 hours[19], but its use leads to a high mortality rate in
experimental animals.
Discussion
In vivo quantification of MSC
This study demonstrates the ability to use 19F-MRI cell tracking to detect and, most important-
ly, to measure the number of transplanted stem cells in vivo. Cell number cannot be quantified
using other MRI cell tracking techniques. Numerous studies have reported on the challenges
associated with quantification of signal loss due to iron-labeled cells.[19,20,35] This has, so far,
narrowed the implementation of cell tracking for monitoring the fate of transplanted cells. In
this study we show excellent correlation between the number of labeled cells implanted and the
number of cells counted on day 0 by 19F-MRI. This capability will pave the way for MRI to be
used for to confirm the delivery of therapeutic cell transplants.
The importance of accurate delivery of cells to a target tissue cannot be overstated. In pre-
clinical investigations often stem cells will be transplanted then a set time allowed to lapse be-
fore the transplanted tissue is removed and processed for microscopy, to determine whether
stem cells remain in the tissue. In many cases only a very small sample of the transplanted tis-
sue is evaluated. In a previous study we used MRI to track iron-labeled MSC in a mouse model
of spinal cord injury[36]. Our in vivo imaging revealed that the challenging intrathecal
Fig 5. Representative endpoint MRI, fluorescence microscopy, and immunohistochemistry acquired at 10x magnification from both implant
models. (A) By day 16, 5/7 immune competent mice had no 19F signal remaining as shown by the representative MRI. The reference tube is marked by “R”.
(B) Fluorescence microscopy of the muscle tissue revealed little red fluorescence remaining in the immune competent mice. No GFP+ mMSCwere
detectable by fluorescence microscopy, suggesting the original mMSC are no longer present. (C) H&E staining reveals the presence of cells at the implant
site which correlate well with the remaining 19F red fluorescence. (D) Immunohistochemistry staining of adjacent tissue sections with the anti-F4/80 antibody
reveals the presence of a few macrophages at this location in the immune competent model. (E) At endpoint, all immune compromised mice had detectable
19F-MRI signal remaining. (F) We observed more red fluorescence from the 19F-label at the transplant site in the immune compromised mice. (G) Once
again, H&E staining in the immune compromised model correlates well with the regions of red fluorescence. (H) Macrophage staining of the immune
compromised model reveals many more F4/80 positive cells at the site of implantation. Furthermore, the fluorescence microscopy of neighboring tissue
sections reveals that the red fluorescence from the 19F agent is in the same location as the macrophages. Once again, scale bars represent 250μm.
doi:10.1371/journal.pone.0118544.g005
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injections of MSC were imprecise approximately 25% of the time; injected cells were often
being deposited in tissue above the cord or leaking out of the cord. The histological assessment
in this study involved the analysis of 1cm of cord tissue on either side of the transplant site, six
weeks after transplantation. Without MRI, a negative observation of MSC by microscopy
would have been taken as failure to engraft rather than due to a missed injection. Injection con-
firmation with 19F MRI would have the additional advantage of determining how many cells
were properly injected and remain at the site.
In a first-in-man study, MRI and scintigraphy were used to assess the success of intranodal
injections consisting of a 1:1 mixture of iron- or indium-labeled dendritic cell (DC) for cancer
therapy in melanoma patients.[37] Despite these cell injections being performed under ultra-
sound guidance the MRI of iron-labeled DC revealed that in 3/8 cases DC were injected near,
but not in, the target lymph nodes.[37] These findings make it clear that the outcome of this
cell therapy on these patients would not be properly evaluated without knowledge of proper de-
livery of DC to the nodes. For DC therapy knowledge of the number of cells delivered to a
lymph node is especially critical since DC migration to nodes correlates with effective stimula-
tion of T cells. 19F-MRI therefore presents a promising solution to the clinical problem of veri-
fying both the location and number of cells within the region of interest immediately following
administration of treatment.
In these experiments the hMSC and the mMSC were both capable of taking up sufficient
19F label for in vivo detection, without decreasing viability below 80%. We observed some vari-
ation in the number of 19F atoms loaded per cell between experiments, although the average
loading was not significantly different for mouse versus human MSC. The cell size is one of the
more important factors influencing the labeling with Cell Sense and mouse and human MSC
are approximately 30 microns in diameter. The fact that it is possible to obtain robust measure-
ments of the number of cells detected by MRI, despite inter-experiment variation in the num-
ber of 19F atoms per cell, is another positive feature of this type of cell tracking. Variation in
19F/cell is not a confounding factor in MRI quantification since the unique cellular loading is
determined for each transplantation. This is particularly important when considering clinical
translation, since 19F uptake is expected to vary between cell donors.
Monitoring the fate of MSC over time
This study also revealed some interesting information about tracking cell fate over time with
19F MRI. We studied the fate of MSC in two different models: mMSC implanted into healthy
wild type C57Bl/6 mice (immune competent model) and hMSC implanted into healthy nude
mice (immune compromised model). The MSC underwent clearance from the sites of implan-
tation in muscle at different rates, which is not unexpected since the two different mouse
strains have very different immune systems.
In the immune competent model, 5/7 mice had no MRI detectable 19F signal remaining at
the site of injection by the endpoint. The other 2 mice had just 4% and 10% of the original sig-
nal remaining. There were no GFP+ cells detected by fluorescence microscopy but there was
some red fluorescence, indicating that some of the 19F label persisted at the site but that it was
not within GFP+ mMSC. The small amount of residual red fluorescent signal corresponded
with F4/80 staining suggesting that some transfer of 19F label from mMSC to macrophages has
occurred. The decline in the signal is likely the result of a number of different things happening
at the transplant site. First, a large number of MSC will die early after their direct transplanta-
tion into a tissue. Second, the label may be diluted by MSC proliferation, or degradation of the
label within MSC. Third, MSC may have migrated away from the implant site; although we did
not detect 19F signal in other nearby locations.
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The fact that for 5/7 mice no MRI signal was detected, even though red fluorescence was
still observed in the tissues (as for the example shown in Fig. 5A-D) is most likely because the
number of cells containing the red fluorescent 19F label is very small and this small amount of
19F signal is below the in vivo detection limits of the MRI protocols used in this study.
In the immune compromised model the 19F signal persisted in all mice until the experimen-
tal endpoint. Much more red fluorescence was observed in these tissues at the implant site and
this corresponded well with F4/80 staining, again suggesting that the persistent 19F signal was
related to transfer of label from hMSC to macrophages. A limitation of this study was that our
hMSC were not also GFP+. This would have allowed us to say with more confidence that the
19F label was associated with macrophages and not the implanted hMSC. Clearance of label
and macrophages may have been slower in these mice because of the inhibited immune system
and lack of rejection response.
Our observation of bystander cell uptake of 19F cell label is supported by a study by Boehm-
Sturm et al.[38] In their study in vivo imaging of the location, density, and survival of neural
stem cells implanted in the brain in a stroke model was performed using 19F MRI in combina-
tion with bioluminescence imaging. The signal from 19F labeled stem cells persisted for more
than 4 weeks after implantation while, over the same time period, the bioluminescence de-
clined, indicating stem cell death. Immunohistochemistry staining also revealed the presence
of microglia/macrophages at the site of implantation.
Terrovitis et al. looked at the retention of iron labeled stem cells implanted into immune
competent rats.[20] Either rat or human cardiac-derived stem cells were injected intramyocar-
dially. In both cases MRI signal loss due to iron was detected for 3 weeks post cell injection and
correlated with the presence of iron containing macrophages in histology. Although the area of
signal void decreased over time substantial signal void persisted at the injection site in all mice.
Since proton MRI is sensitive to even small numbers of iron-labeled cells this form of cell track-
ing is most susceptible to the misinterpretation of cell fate. Previous studies performed in our
lab using iron labeled syngeneic MSC also revealed the persistence of an iron signal void past
21 days in immune competent mice.[14]
Conclusion
In summary, 19F MRI can be used to provide immediate assessment of implanted cells with ex-
cellent correlation between implanted cell number and in vivo quantification. Over time, as the
cells are cleared from the transplantation site, transfer of the 19F label to bystander cells may
confuse interpretation of the change in 19F signal. With the first-in-man studies of 19F MRI re-
cently completed, this result will be particularly relevant when translating this technique into
the clinic.[24]
This work was supported by a research grant from the Ontario Institute for Cancer Re-
search, Smarter Imaging Program. J.M.G. is jointly funded by the Translational Breast Cancer
Research Unit and the Cancer Research and Technology Transfer training program. The fund-
ers had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Supporting Information
S1 Fig. Influence of excitation pulse width and shape on isoflurane detection. (A) Strong
isoflurane signal (red arrow) is detectable following accumulation in the fat pads of mice after
excitation with the standard Gaussian filtered sinc pulse. This signal is affected by a chemical
shift from the fat pad (blue arrow), the fluorine signal in the reference tube experiences does
not shift. By applying a Gaussian filter to the sinc a more rectangular waveform is achieved
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after Fourier transform, but at the cost of broadening the pulse in frequency space. (C) The
mouse was then scanned with a non-filtered sinc pulse. Fourier transform of this pulse pro-
duces a narrower excitation that did not excite isoflurane 19F atoms, preventing background
signal. Both images have been windowed to the same level, and brightened to show the noise
distribution. (B) The filtered pulse shape in time space is shown, with a width of 0.66ms. (D)
The non-filtered sinc pulse width is much broader with a FWHM of 1.32ms in time space. This
produces a narrower pulse in frequency space, preventing the excitation of isoflurane signal.
(TIF)
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